Association Between Serum Advanced Glycation End Products and Cardiovascular‐Kidney‐Metabolic (CKM) Syndrome: A 3‐Year Longitudinal Cohort Study (2019–2022)
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867014112549011456 |
|---|---|
| author | Hui Zhao Ze‐wen Zhang Tao Luo Dilihumaer Aili Wen‐huan Ding Yuan‐yuan Li Yuan‐sheng Gu Shulipan Aslibek Jing‐jing He Wen‐hui Yu Run‐ze Ma Anaer Gaoshao Ting‐ting Qiao Guo‐zhen Zhang Henry S. Lynn Mu‐long Du Jiang‐hong Dai |
| author_facet | Hui Zhao Ze‐wen Zhang Tao Luo Dilihumaer Aili Wen‐huan Ding Yuan‐yuan Li Yuan‐sheng Gu Shulipan Aslibek Jing‐jing He Wen‐hui Yu Run‐ze Ma Anaer Gaoshao Ting‐ting Qiao Guo‐zhen Zhang Henry S. Lynn Mu‐long Du Jiang‐hong Dai Hui Zhao Ze‐wen Zhang Tao Luo Dilihumaer Aili Wen‐huan Ding Yuan‐yuan Li Yuan‐sheng Gu Shulipan Aslibek Jing‐jing He Wen‐hui Yu Run‐ze Ma Anaer Gaoshao Ting‐ting Qiao Guo‐zhen Zhang Henry S. Lynn Mu‐long Du Jiang‐hong Dai |
| collection | Wiley Open Access |
| contents | Association Between Serum Advanced Glycation End Products and Cardiovascular‐Kidney‐Metabolic (CKM) Syndrome: A 3‐Year Longitudinal Cohort Study (2019–2022) Hui Zhao Ze‐wen Zhang Tao Luo Dilihumaer Aili Wen‐huan Ding Yuan‐yuan Li Yuan‐sheng Gu Shulipan Aslibek Jing‐jing He Wen‐hui Yu Run‐ze Ma Anaer Gaoshao Ting‐ting Qiao Guo‐zhen Zhang Henry S. Lynn Mu‐long Du Jiang‐hong Dai Journal of Diabetes ABSTRACTBackgroundCardiovascular‐kidney‐metabolic (CKM) syndrome begins with obesity and glucose abnormalities, advancing to cardiovascular and kidney complications. This study investigates the relationship of advanced glycation end products (AGEs) with CKM syndrome staging and transition patterns.MethodsThis 3‐year longitudinal study (2019–2022) of 1264 adults identified five CKM trajectory groups: Group 1 (stable low‐risk, 6.7%, stage 0/1), Group 2 (fluctuating, 15.8%, stages 0/1–2), Group 3 (stable intermediate, 52.8%, stage 2), Group 4 (progressors, 8.9%, to stage 3/4), and Group 5 (stable high‐risk, 15.8%, stage 3/4), from baseline distributions of stage 0 (1.6%), 1 (12.3%), 2 (71.0%), 3 (5.8%), and 4 (9.2%). Serum AGEs were quantified by UPLC‐MS/MS.ResultsHigher AGEs levels showed significant associations with CKM severity, with each 1‐SD increase corresponding to a 30% greater likelihood of advanced staging (95% CI:10%–54%). Quartile analysis revealed a dose–response relationship (Q2:1.66[1.15–2.41]; Q3:1.67[1.12–2.48]; Q4:1.92[1.31–2.81]). Longitudinally, the total AGEs score was significantly associated with CKM transition patterns from 2019 to 2022. The odds ratios (ORs) for Group 2, Group 3, Group 4, and Group 5 compared to Group 1 were 1.61 (1.06–2.45), 1.64 (1.11–2.41), 1.71 (1.07–2.73), and 2.03 (1.32–3.13), respectively.ConclusionsThese findings suggest that serum AGEs are linked to CKM severity and progression, potentially serving as biomarkers for CKM staging and targets for intervention. 10.1111/1753-0407.70137 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1111/1753-0407.70137 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_1753_0407_70137 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Association Between Serum Advanced Glycation End Products and Cardiovascular‐Kidney‐Metabolic (CKM) Syndrome: A 3‐Year Longitudinal Cohort Study (2019–2022) Hui Zhao Ze‐wen Zhang Tao Luo Dilihumaer Aili Wen‐huan Ding Yuan‐yuan Li Yuan‐sheng Gu Shulipan Aslibek Jing‐jing He Wen‐hui Yu Run‐ze Ma Anaer Gaoshao Ting‐ting Qiao Guo‐zhen Zhang Henry S. Lynn Mu‐long Du Jiang‐hong Dai Journal of Diabetes Association Between Serum Advanced Glycation End Products and Cardiovascular‐Kidney‐Metabolic (CKM) Syndrome: A 3‐Year Longitudinal Cohort Study (2019–2022) Hui Zhao Ze‐wen Zhang Tao Luo Dilihumaer Aili Wen‐huan Ding Yuan‐yuan Li Yuan‐sheng Gu Shulipan Aslibek Jing‐jing He Wen‐hui Yu Run‐ze Ma Anaer Gaoshao Ting‐ting Qiao Guo‐zhen Zhang Henry S. Lynn Mu‐long Du Jiang‐hong Dai Journal of Diabetes ABSTRACTBackgroundCardiovascular‐kidney‐metabolic (CKM) syndrome begins with obesity and glucose abnormalities, advancing to cardiovascular and kidney complications. This study investigates the relationship of advanced glycation end products (AGEs) with CKM syndrome staging and transition patterns.MethodsThis 3‐year longitudinal study (2019–2022) of 1264 adults identified five CKM trajectory groups: Group 1 (stable low‐risk, 6.7%, stage 0/1), Group 2 (fluctuating, 15.8%, stages 0/1–2), Group 3 (stable intermediate, 52.8%, stage 2), Group 4 (progressors, 8.9%, to stage 3/4), and Group 5 (stable high‐risk, 15.8%, stage 3/4), from baseline distributions of stage 0 (1.6%), 1 (12.3%), 2 (71.0%), 3 (5.8%), and 4 (9.2%). Serum AGEs were quantified by UPLC‐MS/MS.ResultsHigher AGEs levels showed significant associations with CKM severity, with each 1‐SD increase corresponding to a 30% greater likelihood of advanced staging (95% CI:10%–54%). Quartile analysis revealed a dose–response relationship (Q2:1.66[1.15–2.41]; Q3:1.67[1.12–2.48]; Q4:1.92[1.31–2.81]). Longitudinally, the total AGEs score was significantly associated with CKM transition patterns from 2019 to 2022. The odds ratios (ORs) for Group 2, Group 3, Group 4, and Group 5 compared to Group 1 were 1.61 (1.06–2.45), 1.64 (1.11–2.41), 1.71 (1.07–2.73), and 2.03 (1.32–3.13), respectively.ConclusionsThese findings suggest that serum AGEs are linked to CKM severity and progression, potentially serving as biomarkers for CKM staging and targets for intervention. 10.1111/1753-0407.70137 http://creativecommons.org/licenses/by/4.0/ |
| title | Association Between Serum Advanced Glycation End Products and Cardiovascular‐Kidney‐Metabolic (CKM) Syndrome: A 3‐Year Longitudinal Cohort Study (2019–2022) |
| topic | Journal of Diabetes |
| url | https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.70137 |